Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

The Centers for Disease Control and Prevention debuted a new public health awareness campaign this week focused on educating ...

Contract manufacturers have carved out a lucrative niche within the biopharma industry, and the value of their collective ...

With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer ...

Lilly has been chasing—and gaining on—its chief metabolic medicine rival Novo Nordisk and its counterpart GLP-1s Ozempic and ...

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...